Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | LGMN | Q99538 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485375 | 0.87 | CYP3A4 (0.53) | CYP3A4HPGDSMN1; SMN2LMNAP2RX7 | |
| SCHEMBL27383556 | 0.86 | CYP3A4 (0.54) | CYP3A4HPGDSMN1; SMN2LMNAP2RX7 | |
| SCHEMBL27385988 | 0.85 | CYP3A4 (0.52) | CYP3A4HPGDSMN1; SMN2LMNAP2RX7 | |
| SCHEMBL25827018 | 0.84 | HPGD (0.57) | CYP3A4HPGDSMN1; SMN2GSK3AGSK3B | |
| SCHEMBL25827046 | 0.84 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL31213513 | 0.83 | HPGD (0.52) | CYP3A4HPGDGSK3AGSK3BCCNB2 | |
| SCHEMBL31213524 | 0.82 | HPGD (0.51) | CYP3A4HPGDSMN1; SMN2GSK3AGSK3B | |
| SCHEMBL29142975 | 0.82 | CYP3A4 (1.00) | CYP3A4HPGDSMN1; SMN2LMNAP2RX7 | |
| SCHEMBL28411396 | 0.82 | CLPP (0.53) | CYP3A4HPGDSMN1; SMN2LMNAP2RX7 | |
| SCHEMBL4847620 | 0.81 | ALDH1A1 (0.50) | CYP3A4SMN1; SMN2LMNAGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066310-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Hangzhou Adamerck Pharmlabs Inc. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4458813-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Hangzhou Adamerck Pharmlabs Inc. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-116410143-A | Polysubstituted uracil derivative, preparation method and application thereof | 杭州奥默医药股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066310-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYMP, UNG, UMPS | CYP3A4 227/4885HPGD 754/4885SMN1; SMN2 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.